Iterum Therapeutics PLC (ITRMF)
Iterum Therapeutics plc is a healthcare company focused on developing and commercializing therapies for drug-resistant bacterial infections in Ireland, Bermuda, and the United States. Its marketed product is ORLYNVAH, an oral penem antibiotic used for uncomplicated urinary tract infections in adult women caused by specified bacteria when treatment alternatives are limited or unavailable. The company is also advancing sulopenem, an anti-infective candidate available in oral and intravenous forms, for a range of bacterial infections including urinary tract, intra-abdominal, respiratory, and certain urogenital indications. Founded in 2015 and headquartered in Dublin, Ireland, Iterum Therapeutics plc is currently in reorganization.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-ITRM.F
|
Not available
|
$9 28,932.3% Upside
|
Not available
|
Bargain
|
Weak
|
0.0%
|
November 12, 2026
|
0.052 K
|
22.733 M
|
95.4%
|
99.2%
|
-123.2
|
72.4%
|
